Aernoud Fiolet

87 Colchicine in Stable Coronary Artery Disease 18. Rajamäki K, Lappalainen J, Öörni K, et al. Cholesterol crystals activate the NLRP3 inflammasome in human macrophages: a novel link between cholesterol metabolism and inflammation. PLoS One. 2010;5(7):e11765. 19. Hornung V, Bauernfeind F, Halle A, et al. Silica crystals and aluminum salts activate the NALP3 inflammasome through phagosomal destabilization. Nat Immunol. 2008;9(8):847-856. 20. Dostert C, Petrilli V, Van Bruggen R, Steele C, Mossman BT, Tschopp J. Innate immune activation through Nalp3 inflammasome sensing of asbestos and silica. Science. 2008;320(5876):674-677. doi:10.1126/science.1156995 [doi] 21. Triantafilou M, Hughes TR, Morgan BP, Triantafilou K. Complementing the inflammasome. doi:10.1111/imm.12556 22. Libby P, Tabas I, Fredman G, Fisher EA. Inflammation and its Resolution as Determinants of Acute Coronary Syndromes. Circ Res. 2014;114(12):1867-1879. doi:10.1161/ CIRCRESAHA.114.302699 23. Martinon F, Pétrilli V, Mayor A, Tardivel A, Tschopp J. Gout-associated uric acid crystals activate the NALP3 inflammasome. Nature. 2006;440(7081):237-241. 24. Terkeltaub RA, Furst DE, Bennett K, Kook KA, Crockett RS, Davis MW. High versus low dosing of oral colchicine for early acute gout flare: Twenty‐four–hour outcome of the first multicenter, randomized, double‐blind, placebo‐controlled, parallel‐group, dose‐comparison colchicine study. Arthritis Rheum. 2010;62(4):1060-1068. 25. Khanna D, Khanna PP, Fitzgerald JD, et al. 2012American College of Rheumatology guidelines for management of gout. Part 2: therapy and antiinflammatory prophylaxis of acute gouty arthritis. Arthritis Care Res (Hoboken). 2012;64(10):1447-1461. 26. Ridker PM, Everett BM, Thuren T, et al. Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease. N Engl J Med. 2017;377(12):1119-1131. doi:10.1056/NEJMoa1707914 27. Huang C, Cen C, Wang C, Zhan H, Ding X. Synergistic effects of colchicine combined with atorvastatin in rats with hyperlipidemia. Lipids Health Dis. 2014;13(1):1. 28. Hollander W, Paddock J, Nagraj S, Colombo M, Kirkpatrick B. Effects of anticalcifying and anti- fibrotic drugs on pre-established atherosclerosis in the rabbit. Atherosclerosis. 1979;33(1):111- 123. 29. Kong J, Deng Y, Dong Q, Liu W, Lu Y. Colchicine Reduces Restenosis after Balloon Angioplasty Treatment for In-Stent Restenosis. Arch Med Res. 2015;46(2):101-106. doi:10.1016/j. arcmed.2015.01.004 30. Crittenden DB, Lehmann RA, Schneck L, et al. Colchicine use is associated with decreased prevalence of myocardial infarction in patients with gout. J Rheumatol. 2012;39(7):1458-1464. doi:10.3899/jrheum.111533 [doi] 31. Solomon DH, Liu CC, Kuo IH, Zak A, Kim SC. Effects of colchicine on risk of cardiovascular events and mortality among patients with gout: a cohort study using electronic medical records linked with Medicare claims. Ann Rheum Dis. November 2015. doi:annrheumdis-2015-207984 32. Deftereos S, Giannopoulos G, Kossyvakis C, et al. Colchicine for Prevention of Early Atrial Fibrillation Recurrence After Pulmonary Vein Isolation: A Randomized Controlled Study. J Am Coll Cardiol. 2012;60(18):1790-1796. doi:10.1016/J.JACC.2012.07.031 33. Deftereos S, Giannopoulos G, Panagopoulou V, et al. Anti-inflammatory treatment with colchicine in stable chronic heart failure: a prospective, randomized study. JACC Hear Fail. 2014;2(2):131- 137.